These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37699634)

  • 41. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review.
    Teo MTW; McParland L; Appelt AL; Sebag-Montefiore D
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):146-158. PubMed ID: 29254769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
    Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
    BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
    Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
    Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Velenik V; Oblak I; Anderluh F
    Radiat Oncol; 2010 Sep; 5():88. PubMed ID: 20920276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
    Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
    Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
    Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A; Lumish M; Sinopoli J; Weiss J; Shia J; Lamendola-Essel M; El Dika IH; Segal N; Shcherba M; Sugarman R; Stadler Z; Yaeger R; Smith JJ; Rousseau B; Argiles G; Patel M; Desai A; Saltz LB; Widmar M; Iyer K; Zhang J; Gianino N; Crane C; Romesser PB; Pappou EP; Paty P; Garcia-Aguilar J; Gonen M; Gollub M; Weiser MR; Schalper KA; Diaz LA
    N Engl J Med; 2022 Jun; 386(25):2363-2376. PubMed ID: 35660797
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
    Yang Z; Gao J; Zheng J; Han J; Li A; Liu G; Sun Y; Zhang J; Chen G; Xu R; Zhang X; Liu Y; Bai Z; Deng W; He W; Yao H; Zhang Z
    Signal Transduct Target Ther; 2024 Mar; 9(1):56. PubMed ID: 38462629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer.
    Somasundaram A; Sanoff HK
    Cancer Cell; 2024 Sep; 42(9):1489-1491. PubMed ID: 39214092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exercise during and after neoadjuvant rectal cancer treatment (the EXERT trial): study protocol for a randomized controlled trial.
    Morielli AR; Usmani N; Boulé NG; Severin D; Tankel K; Nijjar T; Joseph K; Fairchild A; Courneya KS
    Trials; 2018 Jan; 19(1):35. PubMed ID: 29329555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
    Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
    BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
    Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
    Veen T; Kanani A; Lea D; Søreide K
    Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F
    Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.
    Lin Z; Cai M; Zhang P; Li G; Liu T; Li X; Cai K; Nie X; Wang J; Liu J; Liu H; Zhang W; Gao J; Wu C; Wang L; Fan J; Zhang L; Wang Z; Hou Z; Ma C; Yang K; Wu G; Tao K; Zhang T
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.